News
Realty Income: Best In Class Growth, And A Multi-Decade Discount
Earlier this year, we covered Realty Income (NYSE:O) in an article titled: "Realty Income: Over 30%+ Upside To Fair Value".…
Don’t Tell Wall Street: Archer-Daniels-Midland Stock Is A Deep Value Bargain (NYSE:ADM)
Introduction I just wrote an article titled "Betting Big On A Tiny Texan - Why I Just Bought LandBridge." As…
SCHD: This Is Why I Have Turned Bullish Here As A High-Yield Investor
In March this year, I issued a rather pessimistic article on the Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD), recommending investors…
The Dangers Of High Yield Preferreds
There are some excellent opportunities among high yield preferreds with the potential to capture stable double-digit yields. We are also…
Caribou: Analyzing HLA Matching And CB-010’s Clinical Performance (NASDAQ:CRBU)
Thesis Caribou Biosciences, Inc. (NASDAQ:CRBU) recently presented results associated with its product candidate leader, CB-010, Phase 1 clinical trial at…
Aurinia Pharmaceuticals Appears Undervalued (NASDAQ:AUPH)
Shares of one-drug concern Aurinia Pharmaceuticals (NASDAQ:AUPH) have slumped more than 80% from their all-time high as sales of lupus…
Near 52-Week Lows, Molson Coors Beverage Offers A Compelling Value And Income Play (NYSE:TAP)
Poking around companies in the realm of 52-week lows, I came across venerable brewing company Molson Coors Beverage (NYSE: TAP).…
Annovis Bio: A Close Look At Their Parkinson’s Trial Data (NYSE:ANVS)
Annovis Bio's Parkinson's Trial Announcement On Tuesday, July 2, Annovis Bio, Inc. (NYSE:ANVS) announced data from their long-expected phase 3…